Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | UBE2M | P61081 | 6/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800234 | 0.90 | LMNA (0.44) | LMNAUBE2MDCUN1D1KCNH2THRB | |
| SCHEMBL2794648 | 0.90 | UBE2M (0.45) | LMNAUBE2MDCUN1D1OPRM1THRB | |
| SCHEMBL5044720 | 0.89 | UBE2M (0.44) | LMNAUBE2MDCUN1D1KCNH2THRB | |
| SCHEMBL5042237 | 0.89 | ALDH1A1 (0.42) | LMNAUBE2MDCUN1D1KCNH2OPRM1 | |
| SCHEMBL2799801 | 0.89 | UBE2M (0.45) | LMNAUBE2MDCUN1D1OPRM1THRB | |
| SCHEMBL5046584 | 0.88 | UBE2M (0.45) | LMNAUBE2MDCUN1D1OPRM1THRB | |
| SCHEMBL5046704 | 0.88 | UBE2M (0.45) | LMNAUBE2MDCUN1D1OPRM1THRB | |
| SCHEMBL5040065 | 0.88 | UBE2M (0.45) | LMNAUBE2MDCUN1D1OPRM1THRB | |
| SCHEMBL2800239 | 0.88 | LMNA (0.40) | LMNAUBE2MDCUN1D1 | |
| SCHEMBL5040077 | 0.88 | LMNA (0.46) | LMNAUBE2MDCUN1D1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| EP-2468743-A1 | Nitrogen-containing bicyclic compounds useful as antibacterial agents | Toyama Chemical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | LMNA 2947/4885UBE2M 826/4885DCUN1D1 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.